Ferumoxytol is a product candidate for iron replacement therapy in the development pipeline of AMAG Pharmaceuticals Inc, formerly known as Code 7228.
Ferumoxytol has a long blood half-life and may be useful as a blood pool agent in a wide range of applications in MRI. Ferumoxytol is a true intravascular contrast agent that remains in the blood stream for an extended period of time.

Ultrasound imaging is the primary fetal monitoring modality during pregnancy, nevertheless fetal MRI is increasingly used to image anatomical regions and structures difficult to see with sonography. Given its long record of safety, utility, and cost-effectiveness, ultrasound will remain the modality of first choice in fetal screening. However, MRI is beginning to fill a niche in situations where ultrasound does not provide enough information to diagnose abnormalities before the baby's birth. Magnetic resonance imaging of the fetus provides multiplanar views also in sub-optimal positions, better characterization of anatomic details of e.g. the fetal brain, and information for planning the mode of delivery and airway management at birth.

Indications:
Modern fetal MRI requires no sedatives or muscle relaxants to control fetal movement. Ultrafast MRI techniques (e.g., single shot techniques like Half Fourier Acquisition Single shot Turbo spin Echo HASTE) enable images to be acquired in less than one second to eliminate fetal motion. Such technology has led to increased usage of fetal MRI, which can lead to earlier diagnosis of conditions affecting the baby and has proven useful in planning fetal surgery and designing postnatal treatments. As MR technology continues to improve, more advances in the prenatal diagnosis and treatment of fetal abnormalities are to expect. More advances in in-utero interventions are likely as well. Eventually, fetal MRI may replace even some prenatal tests that require invasive procedures such as amniocentesis.

For Ultrasound Imaging (USI) see Fetal Ultrasound at Medical-Ultrasound-Imaging.com.

Quick Overview

A combination of B1 inhomogeneity, poor slice profile, and insufficient spoiler gradients between the refocusing pulse and the readout interval of a spin echo sequence results in a FID signal being detected along with the echo.
Since the FID is not phase encoded (normally the phase encoding occurs before the refocusing pulse), it is not dispersed along the phase encoding axis, but appears as a line across the center of the image.

If the problem persists, it must be addressed by a service representative.

(FE) Echo produced by reversing the direction of the magnetic field gradient to cancel out the position-dependent phase shifts that have accumulated due to the gradient.

See also Gradient Echo Sequence.

(FEDIF) See Out of Phase and Opposed Phase Image.